These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 8921103)

  • 1. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative influence of serum follicle stimulating hormone, age and other factors on ovarian response to gonadotrophin stimulation.
    Cahill DJ; Prosser CJ; Wardle PG; Ford WC; Hull MG
    Br J Obstet Gynaecol; 1994 Nov; 101(11):999-1002. PubMed ID: 7999732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placental protein 14 concentrations in circulation related to hormonal parameters and reproductive outcome in women undergoing IVF/ICSI.
    Westergaard LG; Yding Andersen C; Erb K; Laursen SB; Rasmussen PE; Rex S; Teisner B
    Reprod Biomed Online; 2004 Jan; 8(1):91-8. PubMed ID: 14759294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women.
    Laml T; Obruca A; Fischl F; Huber JC
    Gynecol Endocrinol; 1999 Apr; 13(2):98-103. PubMed ID: 10399054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome.
    Noci I; Maggi M; Fuzzi B; Biagiotti R; Ricci F; Marchionni M
    Gynecol Endocrinol; 2000 Oct; 14(5):321-6. PubMed ID: 11109971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study.
    Howles CM; Loumaye E; Giroud D; Luyet G
    Hum Reprod; 1994 Mar; 9(3):424-30. PubMed ID: 8006130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients.
    Edelstein MC; Brzyski RG; Jones GS; Oehninger S; Sieg SM; Muasher SJ
    J In Vitro Fert Embryo Transf; 1990 Jun; 7(3):172-6. PubMed ID: 2116488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Spanos E; Mantalenakis S
    Hum Reprod; 1995 Oct; 10(10):2545-9. PubMed ID: 8567767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist administration in polycystic ovary syndrome.
    Buckler HM; Phillips SE; Kovacs GT; Burger HG; Healy DL
    Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
    J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsatile subcutaneous versus bolus intramuscular gonadotrophin administration after pituitary suppression with a long-acting gonadotrophin-releasing hormone analogue: a controlled prospective study.
    De Geyter C; De Geyter M; Simoni M; Castro E; Bals-Pratsch M; Nieschlag E; Schneider HP
    Hum Reprod; 1994 Jun; 9(6):1070-6. PubMed ID: 7962378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of buserelin in an IVF programme for pituitary-ovarian suppression prior to ovarian stimulation with exogenous gonadotrophins.
    Ibrahim ZH; Matson PL; Buck P; Critchlow JD; Newman MC; Horne G; Hughes S; Lieberman BA
    Hum Reprod; 1990 Apr; 5(3):258-62. PubMed ID: 2112554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.